Retinal microvasculature and cerebral small vessel disease in the Lothian Birth Cohort 1936 and Mild Stroke Study

Sarah McGrory^{a,b*}, Lucia Ballerini^a, Fergus N. Doubal^a, Julie Staals^{c,d}, Mike Allerhand^{b,e}, Maria del C. Valdes-Hernandez^a, Xin Wang^a, Thomas J. MacGillivray^a, Alex S.F. Doney^f, Baljean Dhillon^a, John M. Starr^{e,g}, Mark E. Bastin^{e,h}, Emanuele Truccoⁱ, Ian J. Deary^{b,e**}, Joanna M. Wardlaw^{e,h,j**}

ABSTRACT

Research has suggested that the retinal vasculature may act as a surrogate marker for diseased cerebral vessels. Retinal vascular parameters were measured using Vessel Assessment and Measurement Platform for Images of the Retina (VAMPIRE) software in two cohorts: (i) community-dwelling older subjects of the Lothian Birth Cohort 1936; and (ii) patients with recent minor ischaemic stroke of the Mild Stroke Study. Imaging markers of small vessel disease (SVD) (white matter hyperintensities [WMH] on structural MRI, visual scores and volume; perivascular spaces; lacunes and microbleeds), and vascular risk measures were assessed in both cohorts. We assessed associations between retinal and brain measurements using structural equation modelling and regression analysis. In the Lothian Birth Cohort 1936 arteriolar fractal dimension accounted for 4% of the variance in WMH load. In the Mild Stroke Study lower arteriolar fractal dimension was associated with deep WMH scores (odds ratio [OR] 0.53; 95% CI, 0.32-0.87). No other retinal measure was associated with SVD. Reduced fractal dimension, a measure of vascular complexity, is related to SVD imaging features in older people. The results provide some support for the use of the retinal vasculature in the study of brain microvascular disease.

^a VAMPIRE project, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

^b Department of Psychology, University of Edinburgh, Edinburgh, UK

^c Department of Neurology, Maastricht University Medical Center, Maastricht, The Netherlands

^d Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands

^e Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, UK

f Division of Cardiovascular and Diabetes Medicine, Medical Research Institute, Ninewells Hospital and Medical School, Dundee, UK

^g Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, UK

^h Scottish Imaging Network, a Platform for Scientific Excellence (SINAPSE) Collaboration, Edinburgh, UK

¹VAMPIRE project, Computing, School of Science and Engineering, University of Dundee, Dundee, UK

^j UK Dementia Research Institute at the University of Edinburgh, Chancellor's Building, Edinburgh, UK

^{*} Corresponding author.

^{**} These authors contributed equally.

Introduction

Presently, the pathogenesis of cerebral small vessel disease (SVD) in humans is not

completely understood, in part due to the difficulty in imaging in vivo the cerebral

microvasculature. Due to the anatomical and physiological similarity of the cerebral and

retinal vessels¹, and the ease with which the retinal microvasculature can be imaged, there has

been considerable interest in determining whether pathologic changes in the retinal vessels

may parallel changes in the cerebral small vessels.

There is strong evidence that retinal vascular features are associated with stroke²⁻³. SVD

stroke subtype⁴⁻⁹, and presence and progression of features of SVD¹⁰⁻¹⁴. However, previous

analyses have focused largely on individual retinovascular signs and individual SVD

markers, rather than considering retinovascular abnormalities or SVD features as a

whole 11,12,15.

We aimed to assess an array of retinal measurements in an effort to identify those most

closely related to individual and total SVD burden independently of any co-association with

common vascular risk factors (VRFs). We hypothesised that associations between

retinovascular changes and SVD lesions would be partly explained by, but remain

independent of, VRFs. We used quantitative retinal measurements, qualitative (visual ratings)

and quantitative indicators of white matter hyperintensities (WMH) (WMH% volume) and

SVD burden, medical-history-derived- and measured vascular risk variables, in two cohorts:

the Lothian Birth Cohort (LBC1936), and the Mild Stroke Study (MSS). The LBC1936

represents a narrow age range at the 'healthy' end of the SVD spectrum. The MSS represents

a wider age range with clinically evident brain vascular disease and a higher burden of SVD

and VRFs. Analysis of these separate but complementary population samples allows us to

examine the relationship between retinovascular and SVD features at different points on the SVD spectrum.

Results

LBC1936

In the LBC1936, 866 participants (448, 52% male) of mean age 72.5 years (SD 0.7) attended for clinical assessment; 681 participants completed brain imaging and provided WMH and SVD ratings and volumes. The 603 participants with retinal imaging measurements available for both right and left eyes provided data as the analytic sample for the present study (Table 1). Of the 603 (303, 50% male), 270 (45%) had hypertension, 58 (10%) had diabetes (Table 1), and 31% had moderate or severe periventricular WMH scores with 19% moderate or severe deep WMH scores (Table 2). Of the 603, 33 participants reported having had a stroke (of whom 11 also had evidence of stroke on imaging), and an additional 51 had imaging-only evidence of a stroke lesion, giving a total with any stroke of 84 (14%).

Table 1. Characteristics of the Lothian Birth Cohort 1936 and the Mild Stroke Study: M (SD) for Continuous Variables and N (%) for Categorical Variables

Variable	Lothian Birth Cohort 1936	Mild Stroke Study
Sample no.	603	155
Age, mean (SD)	72.5 (0.7)	66.9 (11.4)
Sex		
Female	300 (50)	47 (32)
Male	303 (50)	98 (68)
Vascular risk factors		
Hypertension		
No	333 (55)	58 (40)
Yes	270 (45)	87 (60)
Diabetes		
No	545 (90)	126 (87)
Yes	58 (10)	19 (13)
Hypercholesterolemia		
No	375 (62)	88 (62)
Yes	228 (38)	55 (38)
Cholesterol, mmol/L	5.24 (1.16)	4.99 (1.25)
	HbA1c	Blood Glucose, mmol/L
	5.72 (0.60)	6.24 (3.11)
Smoker		
Ex, or never	557 (92)	61 (42)
Yes	46 (8)	84 (58)
Diastolic BP, mm Hg	78.22 (9.59)	85.32 (13.47)
Systolic BP, mm Hg	148.48 (18.99)	150.32 (28.26)

Note. BP=blood pressure; HbA1c=haemoglobin A1c; WMH=white matter hyperintensities

Table 2. Descriptive Statistics for Brain and retinal imaging-derived measurements in the Lothian Birth Cohort 1936 and the Mild Stroke Study: M (SD) for Continuous Variables and N (%) for Categorical Variables

## Brain measurements, mean (SD) WMH % in BTV		idy: M (SD) for Continuous Variables and	
WMH % in BTV	Variable		Mild Stroke Study
WMH % in ICV Ratings Fazekas score (periventricular) 0			
Ratings Fazekas score (periventricular) 17 (4) 6 (4) 1 310 (66) 69 (48) 2 116 (24) 41 (28) 3 28 (6) 29 (20) Fazekas score (deep white matter overall) V 0 77 (16) 22 (15) 1 306 (65) 79 (54) 2 77 (16) 21 (15) 3 11 (2) 23 (16) PVS (basal ganglia) Range: 0-3 Range: 0-1* 0 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds 0 122 (85) 0 47 (10) 22 (85) 1 47 (10) 22 (85) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) 20 (0.64) 2.10 (0.65) BSTDa 2.20 (0.64) 2.10 (0.65) <td></td> <td></td> <td></td>			
Fazekas score (periventricular) 0	WMH % in ICV	0.77 (0.85)	1.33 (1.62)
0 17 (4) 6 (4) 1 310 (66) 69 (48) 2 116 (24) 41 (28) 3 28 (6) 29 (20) Fazekas score (deep white matter overall) 0 77 (16) 22 (15) 1 306 (65) 79 (54) 2 77 (16) 21 (15) 3 11 (2) 23 (16) PVS (basal ganglia) Range: 0-3 Range: 0-1* 0 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds	C		
1 310 (66) 69 (48) 2 116 (24) 41 (28) 3 28 (6) 29 (20) Fazekas score (deep white matter overall) 77 (16) 22 (15) 0 77 (16) 22 (15) 1 306 (65) 79 (54) 2 77 (16) 21 (15) 3 11 (2) 23 (16) PVS (basal ganglia) Range: 0-3 Range: 0-1* 0 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds - - 0 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score - - 0 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD)	Fazekas score (periventricula		
2		17 (4)	6 (4)
3 28 (6) 29 (20) Fazekas score (deep white matter overall) 77 (16) 22 (15) 1 306 (65) 79 (54) 2 77 (16) 21 (15) 3 11 (2) 23 (16) PVS (basal ganglia) Range: 0-3 Range: 0-1* 0 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds - - 0 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score - - 0 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD)		310 (66)	69 (48)
Fazekas score (deep white matter overall) 0 77 (16) 22 (15) 1 306 (65) 79 (54) 2 77 (16) 21 (15) 3 11 (2) 23 (16) PVS (basal ganglia) Range: 0-3 Range: 0-1* 0 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds 0 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score 0 420 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.98 (0.29) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 1.92 (0.04) 1.98 (0.33) LDRa 1.93 (0.04) 1.99 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		116 (24)	41 (28)
0 77 (16) 22 (15) 1 306 (65) 79 (54) 2 77 (16) 21 (15) 3 11 (2) 23 (16) PVS (basal ganglia) Range: 0-3 Range: 0-1* 0 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds - - 0 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score - - 0 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.57 (0.04) 1.58 (0.04) TORTa (log transforme	3	28 (6)	29 (20)
1 306 (65) 79 (54) 2 77 (16) 21 (15) 3 11 (2) 23 (16) PVS (basal ganglia) Range: 0-3 Range: 0-1* 0 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds - - 0 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score - - 0 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) - CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04)	Fazekas score (deep white ma	atter overall)	
2 77 (16) 21 (15) 3 11 (2) 23 (16) PVS (basal ganglia) Range: 0-3 Range: 0-1* 0 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds - - 0 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score - 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) - CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transform	0	77 (16)	22 (15)
11 (2)	1	306 (65)	79 (54)
PVS (basal ganglia) Range: 0-3 Range: 0-1* 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) 3 14 (3) Microbleeds 0 420 (90) 1 122 (85) 1 47 (10) 22 (15) SVD score 0 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 5Da 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) TORTv (log transformed) -9.91 (0.69) BCa 2.09 (0.22) 2.14 (0.30) AFa APa 0.92 (0.04) APa 0.90 (0.05) AFa 0.90 (0.05) 0.88 (0.06)	2	77 (16)	21 (15)
PVS (basal ganglia) 0	3	11 (2)	23 (16)
0 1 (0) 87 (60) 1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds - - 0 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score - - 0 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) - CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv <td>PVS (basal ganglia)</td> <td></td> <td></td>	PVS (basal ganglia)		
1 279 (60) 57 (40) 2 173 (37) - 3 14 (3) - Microbleeds - - 0 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score - - 0 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) - CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.33) 1.98 (0.34) 1.98 (0.33) <td></td> <td>e</td> <td></td>		e	
173 (37) -			
3 14 (3) - Microbleeds 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score - 0 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) - CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.33) 1DRa LDRa 19.37 (5.04) 21.81 (11.21) LDRy 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05)<	=		-
Microbleeds 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) 8 CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRy 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06) <td></td> <td></td> <td>_</td>			_
0 420 (90) 122 (85) 1 47 (10) 22 (15) SVD score		11 (6)	
1 47 (10) 22 (15) SVD score 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) TORAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.99 (0.05) 0.88 (0.06)		420 (90)	122 (85)
SVD score 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)	*	` /	
0 220 (47) 69 (48) 1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		., (10)	22 (10)
1 164 (35) 27 (19) 2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		220 (47)	69 (48)
2 68 (15) 29 (20) 3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)			
3 15 (3) 14 (10) 4 0 5 (3) Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)			` ,
4 0 5 (3) Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		` '	
Retinal measurements, mean (SD) CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		* *	* '
CRAE 31.19 (2.19) 30.93 (2.80) CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)	•		3 (3)
CRVE 42.12 (3.16) 43.67 (3.59) BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)	· · · · · · · · · · · · · · · · · · ·		30.93 (2.80)
BSTDa 2.20 (0.64) 2.10 (0.65) BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		` ,	, ,
BSTDv 3.94 (0.86) 4.01 (0.90) FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)			` ′
FDa 1.59 (0.05) 1.59 (0.05) FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		` /	
FDv 1.57 (0.04) 1.58 (0.04) TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)			, ,
TORTa (log transformed) -9.98 (0.96) -10.01 (0.88) TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		` /	, ,
TORTv (log transformed) -9.91 (0.69) -9.76 (0.73) BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)			
BCa 2.09 (0.22) 2.14 (0.30) BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		` ,	
BCv 1.98 (0.24) 1.98 (0.33) LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		· · · ·	
LDRa 19.37 (5.04) 21.81 (11.21) LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)			
LDRv 18.91 (4.96) 19.55 (5.36) AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)			
AFa 0.92 (0.04) 0.90 (0.05) AFv 0.90 (0.05) 0.88 (0.06)		· · ·	
AFv 0.90 (0.05) 0.88 (0.06)			
			` ,
	AFV	0.90 (0.05)	0.88 (0.06)

Note. BTV=brain tissue volume; ICV=intracranial volume; PVS= perivascular spaces (in basal ganglia); *0: none-mild; 1: moderate-severe. SVD=small vessel disease; CRAE=central retinal arteriolar equivalent; CRVE=central retinal vein equivalent; BSTDa=standard deviation of arteriolar widths in Zone B; BSTDv=standard deviation of venular widths in Zone B; FDa=arteriolar fractal dimension; FDv=venular fractal dimension; TORTa=arteriolar tortuosity; TORTv=venular tortuosity; BCa=arteriolar branching coefficient; BCv=venular branching coefficient; LDRa=arteriolar length diameter ratio; LDRv=venular length diameter ratio; AFa=arteriolar asymmetry factor; AFv=venular asymmetry factor.

Prior to structural equation modelling (SEM), initial analyses in the LBC1936 used regression with 16 retinal variables as exposures and 11 brain variables as outcomes. The results of these multiple linear regression, adjusted for age and sex, are presented in Table 3a. Three of the 176 associations survived adjustment and false discovery rate (FDR) correction. Decreased arteriolar fractal dimension (decreased branching complexity) was associated with greater WMH volume percentage in both brain tissue volume (BTV) (β = -0.203, p < 0.001), and intracranial volume (ICV) (β = -0.203, p < 0.001), and higher Fazekas scores in periventricular regions (β = -0.157, p < 0.001). The following nominally significant age- and sex- adjusted associations attenuated to non-significance with FDR correction: arteriolar fractal dimension with Fazekas scores in deep white matter regions; venular fractal dimension with WMH % BTV and ICV; venular tortuosity with BTV mm³, Fazekas score in deep white matter, perivascular spaces (PVS) score and SVD score; and arteriolar branching coefficient with deep and superficial atrophy ratings, arteriolar asymmetry factor with deep atrophy ratings, and arteriolar length-diameter ratio with ICV (mm³).

The above analyses were re-run after excluding LBC1936 participants with history of stroke (n=84) (Supplementary Table S1). Two additional associations survived adjustment and FDR correction in this sensitivity analysis; decreased venular fractal dimension was associated with increased WMH % in BTV (β = -0.175, p = 0.03) and ICV (β = -0.178, p = 0.03). The three other previously-significant associations with arteriolar fractal dimension remained significant.

Table 3a. Age- and sex- adjusted associations between retinal and brain imaging-derived measurements in Lothian Birth Cohort 1936

															Gradient	Gradient
															a	v
	CRAE	CRVE	BSTDa	BSTDv	FDa	FDv	TORTa	TORTv	BCa	BCv	AFa	AFv	LDRa	LDRv	1 st	1 st
															Unrotated	Unrotated
															PC	PC
	β	β	β	β	β	β	β	β	β	β	β	β	β	β	β	β
WMH % in BTV	091	076	.050	.014	203***	140 ^a	027	.084	.030	019	.008	.031	.069	.018	.025	.025
BTV mm ³	053	.043	089	036	.020	017	035	113 ^a	.029	063	070	042	031	007	.007	.068
WMH % in ICV	091	076	.049	.016	203***	143 ^a	027	.082	.031	019	.008	.028	.073	.021	.025	.026
ICV mm ³	065	.071	099	084	.027	.037	039	083	.008	101	102	.003	131 ^a	082	.007	.075
Fazekas Periventricular	054	.013	.083	.022	157***	080	.000	.083	034	.043	.000	.017	.008	003	.012	011
Fazekas Deep	016	010	.054	.056	118 ^a	084	.008	.113 ^a	010	.023	.014	005	.060	.044	.022	.059
Atrophy Deep	035	007	.024	011	076	.021	.021	.073	.113 ^a	.075	100^{a}	032	038	058	.042	019
Atrophy Superficial	017	007	.044	041	071	.026	.011	.046	.112a	.076	082	001	062	072	024	014
PVS	043	.028	014	044	.041	.080	.010	.146 ^a	005	016	.047	.038	014	.041	.002	029
Microbleeds	020	.003	052	.000	.000	.016	.028	018	062	024	.025	.032	.019	067	039	048
SVD score	059	.009	005	009	051	.025	.007	.141 ^a	029	.018	.040	.024	.033	.001	.037	005

Note. Model adjusted for age and sex. WMH=white matter hyperintensities; BTV=brain tissue volume; ICV=intracranial volume; PVS= basal ganglia perivascular spaces; SVD=small vessel disease; CRAE=central retinal artery equivalent; CRVE=central vein retinal equivalent; BSTDa=standard deviation of arteriolar widths in Zone B; BSTDv=standard deviation of venular widths in Zone B; FDa= fractal dimension arteriolar; FDv=fractal dimension venular; TORTa= arteriolar tortuosity; TORTv=venular tortuosity; BCa=arteriolar branching coefficient; BCv=venular branching coefficient; AFa=arteriolar asymmetry factor; AFv=venular asymmetry factor; LDRa=arteriolar length diameter ratio; LRDv= venular length diameter ratio; Gradient a= arteriolar width gradient; Gradient v= venular width gradient; PC=principal component; Bolded values are statistically significant. WML % volumes and tortuosity log transformed. β, Standardised regression coefficients.

^{* =} p < .05; ** = p < .01; *** = p < .001; all p-values corrected for False Discovery Rate. a = value was statistically significant at p < .05 before FDR correction

Measurement models in SEM to derive the latent traits of VRF, 'WMH load', 'SVD burden' and retinal 'calibre-complexity' in the LBC1936 sample (Supplementary Fig. S1-S3) indicate that almost all measured variables contributed significantly to their hypothesised latent variable (with parameter weights with p < 0.05). The exceptions were: smoking (p = 0.34), as found in the VRF latent variable derived previously in the LBC1936¹⁶; and microbleeds in the SVD latent trait (p = 0.29). Nonetheless, these variables were included in the VRF and SVD latent traits. All models had acceptable fit to the data (Supplementary Fig. S1-S3).

SEMs used to test hypothesized relationships among latent variables of 'calibre-complexity' and 'WMH load' and 'SVD burden' in LBC1936 are shown in Figure 1. In addition to the contributions of age, sex and VRFs, 'calibre-complexity' was significantly associated with the latent traits of WMH load (standardised parameter weight -0.181, p < 0.001) (Figure 1A) and SVD burden (standardised parameter weight -0.141, p = 0.021) (Figure 1B). This retinal construct of vessel calibre and branching complexity accounted for approximately 3.3% and 2.0% of the variance in WMH load and SVD burden, respectively. However, the association between 'calibre-complexity' and SVD burden attenuated to non-significance once corrected for multiple comparisons (p = 0.054).




Figure 1. Structural models for retinal latent traits predicting WMH/SVD burden in the LBC1936

(a) Model of retinal calibre-complexity predicting WMH Load; (b) Model of retinal calibre-complexity predicting SVD burden; Standardised regression coefficients (parameter weights) are shown adjacent to each path. P-values corrected for False Discovery Rate. The rectangles to the left are the covariates in the model. Each of the covariates was examined for their contribution to VRF, 'Calibre-complexity' and WMH Load/SVD Burden, and only significant (p < .05) contributions are shown. VRF = vascular risk factor; WMH = white matter hyperintensities; SVD = small vessel disease. Dashed lines represent non-significant associations; dotted line represents nominally significant association.

SEMs used to test hypothesized relationships among individual retinal variables (identified from age- and sex- adjusted regression models, see Table 3), and latent constructs of WMH load and SVD burden in LBC1936 are shown in Figures 2. In addition to the contributions of age, sex and VRFs, reduced arteriolar fractal dimension was significantly associated with the latent traits of WMH load (standardised parameter weight -0.211, p < 0.001) (Figure 2A) and SVD burden (standardised parameter weight -0.168, p = 0.002) (Figure 2B), accounting for approximately 4.4% and 2.8% of the variance in WMH and SVD respectively. These associations survived FDR correction. The VRF latent trait was not significantly associated with fractal dimension or either SVD or WMH latent trait (Figure 2).




Figure 2. Structural models for retinal fractal dimension measurements predicting WMH/SVD burden in the LBC1936

(A) Model of FDa predicting WMH Load; (B) Model of FDa predicting SVD burden; Standardised regression coefficients (parameter weights) are shown adjacent to each path. P-values corrected for False Discovery Rate. The rectangles to the left are the covariates in the model. Each of the covariates was examined for their contribution to VRF, FDa and WMH Load/SVD Burden, and only significant (p < .05) contributions are shown. FDa = arteriolar fractal dimension; VRF = vascular risk factor; WMH = white matter hyperintensities; SVD = small vessel disease. Dashed lines represent non-significant associations.

We tested additional SEMs—to test for co-association of retinal and SVD indicators with

VRFs—of the three relationships between retinal variables and individually-measured brain

imaging variables that had surviving age-, sex-, and FDR adjustment (Table 3a). The results

are shown in Supplementary Fig. S13. All retinal-brain associations remained significant and

survived FDR correction.

MSS

Among those participants of the MSS cohort with retinal images of both eyes available for

analysis (n=155; 98, 68% male), of mean age 66.9 years (SD 11.4), 87 (60%) had

hypertension, 19 (13%) had diabetes (Table 1). Seventy (48%) had moderate or severe

periventricular WMH scores, and 44 (30%) with moderate or severe deep WMH scores

(Table 2).

In age- and sex-adjusted linear regression models, only one association remained significant

following correction for FDR; reduced arteriolar fractal dimension was significantly

associated with higher WMH scores in deep white matter regions ($\beta = -0.327$, p < 0.001). The

following 12 nominally significant age- and sex- adjusted associations attenuated to non-

significance after applying FDR correction: central retinal artery equivalent (CRAE) with

WMH % BTV and ICV, variation in arteriolar widths with WMH % BTV and ICV; variation

in venular widths with WMH % in BTV and ICV and Fazekas scores in deep white matter;

arteriolar fractal dimension with WMH % in BTV, ICV, Fazekas scores in periventricular

region, and SVD score; and venular branching coefficient and Fazekas score in deep white

11

matter region (Table 3b).

Table 3b. Age- and sex- adjusted associations between retinal and brain imaging-derived measurements in MSS

															Grad a	Grad v
	CRAE	CRVE	BSTDa	BSTDv	FDa	FDv	TORT	TORTv	BCa	BCv	AFa	AFv	LDRa	LDRv	1 st	1 st
							a								Unrotated	Unrotated
															PC	PC
	β	β	β	β	β	β	β	β	β	β	β	β	β	β	β	β
WMH in BTV	269 ^a	035	270 ^a	392 ^a	365ª	094	055	252	044	134	026	021	062	036	199	036
BTV mm ³	.040	067	.226	.147	064	007	074	.209	.242	115	.186	017	.187	137	.037	080
WMH in ICV	266 ^a	036	257 ^a	383ª	370 ^a	091	049	247	044	136	018	028	063	036	202	033
ICV mm ³	.004	069	.006	.015	.046	029	175	.129	.257	082	.084	.129	.216	118	.113	121
Fazekas Peri	177	046	105	133	308 ^a	085	039	.030	123	193	.021	018	118	017	009	054
Fazekas Deep	187 ^a	025	026	115	327***	.026	.026	.161	087	216 ^a	.169	033	122	124	.027	050
Atrophy Deep	095	050	194	260 ^a	157	.035	022	016	144	.092	.027	.070	147	.128	.032	011
Atrophy Superficial	168	039	170	101	118	069	070	085	026	.038	.029	029	046	.085	.124	.011
PVS	152	.043	053	097	158	.007	.020	.035	.120	032	025	018	.021	118	050	141
Microbleeds	146	.096	033	073	142	.024	120	.071	047	125	.087	113	090	171	.123	170
SVD score	158	.016	024	100	274ª	.004	029	.095	.085	145	.065	034	.016	145	.042	105

Note. Model adjusted for age and sex. WMH=white matter hyperintensities; BTV=brain tissue volume; ICV=intracranial volume; PVS= basal ganglia perivascular spaces; SVD=small vessel disease; CRAE=central retinal artery equivalent; CRVE=central vein retinal equivalent; BSTDa=standard deviation of arteriolar widths in Zone B; BSTDv=standard deviation of venular widths in Zone B; FDa= fractal dimension arteriolar; FDv=fractal dimension venular; TORTa= arteriolar tortuosity; TORTv=venular tortuosity; BCa=arteriolar branching coefficient; BCv=venular branching coefficient; AFa=arteriolar asymmetry factor; AFv=venular asymmetry factor; LDRa=length diameter arteriolar; LDRv=length diameter ration venular; PC=principal component; Bolded values are statistically significant. WML % volumes and tortuosity log transformed. β. Standardised regression coefficients

^{* =} p < .05; ** = p < .01; *** = p < .001; All p-values corrected for False Discovery Rate. ^a = value was statistically significant at p < .05 before FDR correction

We conducted further multivariable ordinal regression analysis on the surviving association between arteriolar fractal dimension and deep white matter Fazekas score, introducing the VRF component as an additional covariate to age and sex (Table 4). Lower arteriolar fractal dimension remained significantly associated with deep WMH Fazekas scores, with OR (95% CI) of 0.53 (0.32-0.87).

Table 4. Multivariate regression analysis of brain imaging-derived measurements of SVD in the Mild Stroke Study. All variables in column 1 were entered simultaneously as independent variables in the models

	Fazekas Dee	p†
	OR (95% CI)	p
Male	1.23 (0.49; 3.42)	0.596
Age	2.30 (1.45; 3.65)	<.000
VRF	0.85 (0.54; 1.33)	0.474
FDa	0.53 (0.32; 0.87)	0.012

Note. Multivariate analysis with correction for all variables in the table. OR=odds ratio; CI=confidence interval; FDa=arteriolar fractal dimension; SVD=small vessel disease. † Ordinal regression with Fazekas score (0-3) as dependent variable. Continuous predictors were converted to z-scores.

Discussion

To our knowledge, the current study is the first that uses SEM to investigate the relationship between retinal microvascular and brain imaging markers of SVD. Whereas our retinal data reduction approach found most retinal measurements to be largely independent, i.e. not indicators of the same latent trait, we did find four retinal variables with considerable shared variance reflecting aspects of geometry, namely vessel width and complexity. This combined vessel calibre-complexity latent trait was related to SVD burden and WMH load in the LBC1936. Examining retinal variables individually in the LBC1936, we found participants with decreased arteriolar fractal dimension, suggesting of a loss of branching complexity, were more likely to have greater cerebral SVD pathology, independent of VRF. Sparser arteriolar microvasculature was also associated with more WMH. All effect sizes were small. The relatively larger effect sizes of the results using individual retinal variables suggest that

the relationship between 'calibre-complexity' and SVD burden is largely driven by the effect

of reduced arteriolar fractal dimension. Findings were generally consistent in the MSS

participants despite the wider age range and increased burden of vascular disease; MSS

participants with sparser arteriolar fractal dimension were more likely to have more WMH in

deep white matter. Our results are in line with those of Wardlaw et al. (2014) in reporting that

VRFs only account for a small proportion of the variance in WMH¹⁶. Our findings add

further weight to the concept that easy to measure, common VRFs explain only a small

proportion of both variance in retinal vascular and brain SVD features, leaving a large

proportion unexplained.

These findings add further support to the hypothesis that retinal fractal dimension, as a global

summary measure of the state or health of the retinal vasculature, might have a significant

association with the changes taking place in cerebral small vessels. A loss of branching

complexity in regulatory systems of other organs of the body is thought to occur as they

become less complex with age¹⁷. In line with our results, Hilal et al. (2014) found those with

reduced arteriolar fractal dimension were more likely to have cerebral microbleeds¹¹.

Reduced fractal dimension has also been found in Alzheimer's disease 18-20. Decreased

branching complexity of the arteriolar and venular networks combined in lacunar stroke, a

manifestation of SVD, has previously been reported in the MSS cohort⁶.

A large number of association tests were conducted, and several significant associations

became non-significant once corrected for multiple testing. Whereas the amount of

associations conducted increases the likelihood of type-1 errors, it is also possible that our

robust correction for multiple testing is rejecting modest but true associations; larger sample

sizes are needed to confirm them²¹. We interpret all unadjusted significant associations

cautiously as they may reflect spurious associations. However, they could provide directions

for future research. Without adjustment, some additional retinal measurements, including

venular tortuosity and arteriolar measures of branching geometry, appeared relevant for some

markers of SVD.

A limitation of the study is its cross-sectional design. Longitudinal studies examining retinal

changes and progression of SVD and WMH would be valuable. The smaller sample size of

the MSS cohort did not allow for consistent statistical methods across cohorts. Furthermore,

despite the use of a validated semi-automated software application; VAMPIRE (Vessel

Assessment and Measurement Platform for Images of the Retina, version 3.1, Universities of

Edinburgh and Dundee), a degree of subjective human interaction introduces potential for

intra-grader variability. Sources of variability of retinal measurements from fundus images

have been discussed, among others, in Trucco et al. (2013)²². We also acknowledge our

retinal variables data reduction approach represents a first step towards a composite measure

of abnormality and subsequent choice of variables is not definitive. Other studies may reach

different conclusions based on their data. The participants' age may have reduced the strength

of the associations between VRF, WMH and retinal measurements. The relationship between

WMH and hypertension appears stronger in middle age²³. A systematic review of

associations between retinal microvascular changes, dementia and brain imaging features

reported stronger findings in middle-aged populations²⁴, in line with the age-related

attenuation of associations between VRFs, hypertension and cerebrovascular disease and

retinopathy^{25, 26}.

The strengths of the current study include the use of two distinct, yet complementary, well-

characterised cohorts. This provides a more comprehensive account of the relationship

between the retinal and cerebral microvasculature in different populations, representing different points on the SVD continuum. Furthermore, the LBC1936 as a narrow-age cohort, reduces the troublesome problem where chronological age confounds the influence of other variables. All LBC1936 and MSS participants were imaged using the same retinal camera and MRI scanner, at the same time period, according to the same brain and retinal image analysis methods. This included the use of standardised retinal and cerebral examinations and the use of both quantitative and qualitative WMH measures with the careful exclusion of infarcts from WMH volume. Additional strengths include the use of robust statistics. The sample size in the LBC1936 allowed us to account for measurement error by using SEM to derive error-free latent contracts for VRF, WMH and SVD.

In summary, we provide some evidence to support concomitant retinal and cerebral microvasculature changes, with a small but significant association between reduced retinal arteriolar branching complexity and SVD pathology, known to represent a significant risk factor for dementia and stroke²⁷. That sparser vasculature is associated with WMH and SVD burden, suggests that the retinal microvasculature can exhibit corresponding microvascular signs of altered vascular competence leading to tissue damage in the brain. These data extend the research potential of retinal imaging beyond the eye in studying neurovascular disease¹ and paves the way for further studies into mechanism of dementia and stroke and possibly to refine the prognostic potential of detailed retinal microvascular analysis, although we again note that the associations are small. The added value of embedding retinal image analytics in cross-linked health datasets to study SVD is yet to be determined; this requires intra-individual change detection in stratified prospective cohorts to be tracked. As a cross-sectional study, we can only determine associations not causation, nor the progression of cerebral SVD. Despite our efforts in judging the statistical significance of the results with FDR correction, the associations found in this study need future replication in independent

samples. Careful validation of our findings is required for better characterizing the retinal

changes accompanying SVD, and in considering whether retinal measures have a place in

clinical work such as in screening or as outcomes in trials. Further studies are required to

elucidate whether changes to retinal properties precede pathology or a response to long-term

exposure to risk factors.

Methods

Participants

The LBC1936²⁸ comprised community-dwelling, mostly healthy older adults, of mean age

about 70 years when first recruited in older age. All were born in 1936. The data analysed for

the present study, including digital retinal photographs and structural brain imaging, were

obtained at a second wave of testing when the participants were approximately 73 years old

(N=866). The recruitment and testing of the LBC1936 has been described in detail

previously²⁸⁻³⁰.

The Mild Stroke Study (MSS)⁴ is a prospective study of patients with recent (within 3

17

months) clinical lacunar or mild cortical ischaemic stroke. All patients were assessed by an

experienced stroke physician. The recruitment, testing and imaging of these patients has been

described previously^{4,10}.

Both studies were approved by Lothian Research Ethics (LBC1936: REC 07/MRE00/58;

MSS: 2002/8/64). The LBC1936 study was also approved by the Scottish Multicentre

(MREC/01/0/58) Research Ethics. Written informed consent for participation in both studies

was obtained from all participants. The research was carried out in compliance with the

Helsinki Declaration.

Measures

Retinal image acquisition and analysis

In both groups, digital retinal fundus images were captured using the same non-mydriatic camera at 45° field of view (CRDGi; Canon USA, Lake Success, New York, USA). 814 LBC1936 (from Wave 2 of testing) and 190 MSS participants provided retinal images of both eyes. Images were centred approximately on the optic disc. For the present analysis, the retinal images were reanalysed for retinal vascular characteristics using the same semiautomated software package, VAMPIRE by an experienced operator. VAMPIRE image processing and analysis has been described in detail previously³¹⁻³³. Briefly, the boundaries of the optic disc (OD) and position of the fovea in a retinal image are first detected and the conventional set of OD-centred circular measurement zones established. Zone B is a ring 0.5 to 1 OD diameters away from the centre, and Zone C is a ring extending from OD boundary to 2 OD diameters away. Next, the software detects the retinal blood vessels present in the image and classifies them as arterioles or venules. The observer, when necessary followed a standardised measurement protocol to preform manual interventions to correct computergenerated labelling of image features, blind to all prior retinal analysis, brain and VRF data. There were complete retinal measurements from both eyes for 603 LBC1936 and 155 MSS participants. Rejections were due to poor quality images, eyelashes causing streaks across the photograph, out-of-focus images, and overexposure (in either eye); these occurred in approximately 16% of LBC1936 images, and 8% of MSS images, with an additional 4% of MSS images excluded due to considerable differences in image resolution (arising from deviations from standard operation of the system when imaging).

Sixteen retinal vascular parameters were measured from each image in both cohorts: measures of vessel calibre—central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and the variation in calibre—the standard deviation of arteriolar and venular widths (BSTDa, BSTDv); the gradient of the width of the main arteriolar and venular vessel paths (GRADa, GRADv); measures of branching complexity—arteriolar and venular fractal dimension (FDa, FDv); measures of vessel tortuosity—arteriolar and venular tortuosity (TORTa, TORTv); and measures of arteriolar and venular branching geometry—branching coefficient (BCa, BCv), length-diameter ratio (LDRa, LDRv) and asymmetry factor (AFa, AFv). A lowercase 'a' or 'v' following the variable name indicates a measurement of arteriolar or venular vessels respectively. See supplementary material for details on all retinal measurements and how retinal variables were selected for analysis. To reduce the number of variables, reduce multicollinearity and increase reliability, the above-mentioned measurements from both eyes of each participant were averaged to provide a mean measurement for all variables.

MRI brain image acquisition and processing

LBC1936 and MSS participants (at time of presentation) underwent brain MRI on the same 1.5-Tesla GE Signa Horizon HDx clinical scanner (General Electric, Milwaukee, WI) with T1-, T2- and T2*- weighted and fluid-attenuated inversion recovery (FLAIR) axial whole-brain imaging. Full details of the brain imaging scanning protocol for the LBC1936 and MSS have been described previously^{10,30}. All analyses were performed blinded to all other data. The SVD lesions in both studies were assessed qualitatively and quantitatively using validated methods according to a precursor to the STRIVE criteria³⁴. WMH were visually scored using FLAIR-, T1 and T2-weighted sequences on the Fazekas score³⁵ in both the deep (0-3) and periventricular (0-3) white matter. Appropriate sequences were also rated for the

presence of microbleeds (location and number), lacunes (location and number), and

perivascular spaces (in basal ganglia and centrum semiovale, 0-4 point score each) according

to an established rating protocol³⁶. Brain atrophy was coded using a validated template³⁷,

with superficial and deep atrophy coded separately.

We combined the visual lesion scores into an ordinal 'total SVD score' of 0-4, described

previously³⁸. Briefly, a scale point was awarded for the presence of (early) confluent deep (2-

3) WMH and/or irregular periventricular WMH extended into the deep white matter (3); one

or more lacunes; one or more microbleeds; and moderate to severe grading (2-4) of basal

ganglia perivascular spaces. These showed face-validity both as an ordinal score and as a

latent variable in previous analyses both in the present cohorts and in other studies^{38,39}. All

rating was performed by a consultant neuroradiologist trained and experienced in SVD

features and use of the visual ratings. Quality control of images has been described

previously^{16,39}.

Ouantitative measures of WMH, brain and intracranial volume were obtained using T2*-

weighted and FLAIR sequences with a validated semi-automated multispectral image

processing tool, MCMxxxVI⁴⁰. This tool was used to measure intracranial volume (ICV, soft

tissue structures within the cranial cavity including brain, cerebrospinal fluid, dural and

venous sinuses), brain tissue volume (BTV, intracranial volume excluding the ventricular

cerebrospinal fluid) and WMH. The structure volumes were measured as absolute values in

cubic millimetres (BTV mm³, ICV mm³). Quantitative measures of WMH were expressed as

20

percentage of WMH volume in ICV (WMH % ICV) and percentage of WMH volume in

BTV (WMH % BTV).

Covariates

Age and sex were included as covariates in both the LBC1936 and MSS samples. Measures of vascular risk were included as covariates in both samples. VRFs were assessed in the LBC1936 subjects at age ~73 years, at the same session as the retinal photography, and a mean (SD) of 9 (5) weeks prior to brain imaging; they were assessed on presentation in the MSS, at the same time as brain imaging, and approximately four weeks prior to retinal photography. A combination of medical history variables (medically diagnosed hypertension, diabetes, smoking, and hypercholesterolemia), and measured variables (blood pressure [BP], haemoglobin A1c, and plasma cholesterol) were used. The average of three sitting BP measurements were used to derive mean systolic and mean diastolic BP variables in LBC1936 and one BP reading was used for MSS subjects. The above measures were recorded for MSS subjects with the exception of haemoglobin A1c. All measures were performed blinded to all other data. Variables were selected based on a set of measures of vascular risk that we had identified contributed to vascular risk of WMH in previous LBC1936 and MSS analysis ¹⁶.

Statistical analysis

Age- and sex-adjusted linear regression was used to analyse the association between the 16 retinal vascular characteristics and the structural brain imaging-derived measurements in both cohorts. To minimise the potential for type I errors, p values were adjusted according to the false discovery rate (FDR) method⁴¹. LBC1936 participants with a history of stroke (n=84, 14%; based on medical history and/or brain imaging appearances) were removed in a sensitivity analysis. Due to the small size and insufficient stroke classification this group could not be divided into stroke subtypes. VRFs were tested as possible explanatory variables for any significant associations between retinal and brain imaging variables, since both retinal vascular abnormalities and SVD features are known to be associated with common VRFs

such as hypertension, smoking, diabetes, etc.; this was examined using SEM in LBC1936,

and multivariable regression models in the MSS cohort (which we judged to be too small for

SEM). See Penke and Deary (2010) for an accessible description of SEM as applied in

neuroscience⁴².

The basic questions in the analyses were whether retinal vessel measures were associated

with brain imaging measures, and whether these associations were co-associated with VRFs.

The LBC1936 is both large in size and has multiple measures of brain white matter health

and VRFs. Therefore, in testing the questions above, we were able to form multi-variable

'latent traits' (unobservable constructs underlying a combination of correlated individual

measured variables) for retinal features, white matter health, and vascular risk. Results from

the regression analyses in the LBC1936 were used to motivate the hypothesized relationships

subsequently to be tested by SEM.

We showed previously that VRFs, WMH measures and SVD features formed latent variables

in the LBC1936^{16, 39,43}. Therefore, we used the same measurement models to derive the latent

variables. Vascular risk was measured as a single latent factor from eight variables;

hypertension, diabetes, hypercholesterolemia, smoking, (treated) systolic and diastolic BP,

haemoglobin A1c, and plasma cholesterol, as previously¹⁶. The volume of WMH as a

percentage of ICV, and Fazekas ratings in periventricular and deep white matter were used to

derive a latent variable of 'WMH load' as previously⁴³. 'SVD burden' was measured using a

single latent factor with five indicators, namely, Fazekas ratings for both periventricular and

deep regions, lacunes, microbleeds, and basal ganglia perivascular spaces, as previously³⁹.

This was undertaken to test whether including three additional imaging markers of SVD

might increase the ability to find significant associations. A single latent 'calibre-complexity'

factor was derived from four retinal indicators; two measures of vessel width (CRAE,

CRVE), and two measures of branching complexity; arteriolar and venular fractal dimension.

The derivation of this latent variable is described fully in the Supplementary Material. All

models were estimated using R's lavaan SEM package, version 0.5-22⁴⁴.

Models were estimated using the robust (mean and variance adjusted) weighted least squares

(WLSMV) estimator. WLSMV is robust to non-normality and is appropriate for model

estimation with categorical data. Standardised regression coefficients (parameter weights,

comparable to standardised partial beta weights) were computed for each path in the models.

Model fit was assessed using cut-off points of > 0.06 for the root mean square error of

approximation (RMSEA), and ≥ 0.90 for the comparative fit index (CFI) and Tucker-Lewis

index (TLI). Measurement models for latent traits are shown in Supplementary Fig. S1-S3.

We tested the same two questions in the MSS as above for the LBC1936. However, due to

the smaller sample size, latent variables were not formed in MSS and we did not use SEM to

test hypotheses. Instead, multivariable regression models were applied in the MSS to test for

associations between retinal and brain imaging-derived measurements, and the controls were

applied for age, sex, and VRFs. To reduce the number of vascular risk parameters and the

likelihood of type I errors, principal components analysis (PCA) was applied to the eight

measured VRF variables in MSS. The first unrotated principal component accounted for a

substantial percentage of the overall variance in VRF variables (26%), with loadings ranging

between 0.18 and 0.77, and was used to generate a general VRF score. To validate the use of

a principal component score, factor scores for VRFs were derived using the same PCA

method in the LBC1936 sample. The correlation between the VRF principal component score

from PCA analysis and the VRF latent trait obtained using SEM in the LBC1936 was very

strong (r = 0.89). Multivariable ordinal regression analysis was used for WMH and SVD

scores in MSS. Results are presented as odds ratio (OR) with 95% confidence interval (CI).

Predictors were converted to z-scores, such that the resulting ORs reflect the odds of having

higher pathology ratings for each standard unit increase in the predictor variable. Regression

analyses were performed with SPSS statistics version 22 (IBM Corp., Armonk, NY).

Acknowledgements

The authors thank the Lothian Birth Cohort 1936 members and participants of the Mild

Stroke Study who took part in this study; the radiographers at the Brain Research Imaging

Centre; the nurses of the Wellcome Trust Clinical Research Facility and the members of the

LBC1936 research team who collected and collated the LBC1936 data we analysed. The

Lothian Birth Cohort 1936 is supported by Age UK (Disconnected Mind project) and the

Medical Research Council (MR/M01311/1). Support from NHS Lothian R&D, and

Edinburgh Imaging and Edinburgh Clinical Research Facility at the University of Edinburgh

is gratefully acknowledged. Retinal photographs were taken in the Wellcome Trust Clinical

Research Facility, Western General Hospital, Edinburgh. We thank Stuart J. Ritchie for

statistical advice and guidance. The work was undertaken in The University of Edinburgh

Centre for Cognitive Ageing and Cognitive Epidemiology, which is supported by funding

from BBSRC and the Medical Research Council (MRC) as part of the cross council Lifelong

24

Health and Wellbeing Initiative (MR/K026992/1). The work was partially supported by

EPSRC project EP/M005976/1 "Multimodal retinal biomarkers for vascular dementia".

Competing interests

The authors declare no conflicts of interest.

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Author contributions

The author contributions are as follows for each of the categories listed. Study conception and design, acquisition/analysis/interpretation of data: SM, IJD, JMW, FND, TJM, ET. Image processing: SM, MVH, XW, MEB. Drafting the article or revising it critically: SM, LB, FND, JS, MA, MVH, XW, TJM, ASFD, BD, JMS, MEB, ET, IJD, JMW

References

- 1. Patton, N. et al. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. *J. Anat.* **206**(4), 319-48 (2005).
- 2. Doubal, F. N., Hokke, P. E. & Wardlaw, J.M. Retinal microvascular abnormalities and stroke: a systematic review. *J. Neurol. Neurosurg. Psychiatry.* **80**(2), 158-65 (2009).
- 3. McGeechan, K. et al. Prediction of incident stroke events based on retinal vessel caliber: a systematic review and individual-participant meta-analysis. *Am. J. Epidemiol.* **170**(11), 1323-32 (2009).
- 4. Doubal, F.N. et al. Differences in retinal vessels support a distinct vasculopathy causing lacunar stroke. *Neurology*. **72**(20), 1773-8 (2009).
- 5. Doubal, F. N., Dhillon, B., Dennis, M. S. & Wardlaw, J. M. Retinopathy in ischemic stroke subtypes. *Stroke*. **40**(2), 389-93 (2009).
- 6. Doubal, F. N. et al. Fractal analysis of retinal vessels suggests that a distinct vasculopathy causes lacunar stroke. *Neurology*. **74**(14), 1102-7 (2010).
- 7. Cheung, N. et al. Retinal fractals and acute lacunar stroke. *Ann. Neurol.* **68**(1), 107-11 (2010).
- 8. Lindley, R. I. et al. Retinal microvasculature in acute lacunar stroke: a cross-sectional study. *Lancet Neurol.* **8**(7), 628-34 (2009).
- 9. Yatsuya, H. et al. Retinal microvascular abnormalities and risk of lacunar stroke: Atherosclerosis Risk in Communities Study. *Stroke.* **41**(7), 1349-55 (2010).

- 10. Doubal, F. N. et al. Retinal arteriolar geometry is associated with cerebral white matter hyperintensities on magnetic resonance imaging. *Int. J. Stroke.* **5**(6), 434-9 (2010).
- 11. Hilal, S. et al. Microvascular network alterations in retina of subjects with cerebral small vessel disease. *Neuroscience Lett.* **577**, 95-100 (2014).
- 12. Ikram, M. K. et al. Retinal vessel diameters and cerebral small vessel disease: the Rotterdam Scan Study. *Brain.* **129**(1), 182-8 (2005).
- 13. Mutlu, U. et al. Retinal microvasculature and white matter microstructure The Rotterdam Study. *Neurology*. **87**(10), 1003-10 (2016).
- 14. Qiu, C. et al. Differential associations between retinal signs and CMBs by location: The AGES-Reykjavik Study. *Neurology*. **90**(2), e142-8 (2018).
- 15. Kwa, V. I. H., Van der Sande, J. J., Stam, J., Tijmes, N. & Vrooland, J. L. Retinal arterial changes correlate with cerebral small-vessel disease. *Neurology*. **59**(10), 1536-40 (2002).
- 16. Wardlaw, J. M. et al. Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities. *Neurology*. **82**(15), 1331-8 (2014).
- 17. Lipsitz, L.A. & Goldberger, A.L. Loss of complexity and aging. *Jama.* **267**(13), 1806-9 (1992).
- 18. Cheung, C.Y. et al. Microvascular network alterations in the retina of patients with Alzheimer's disease. *Alzheimers Dement.* **10**(2), 135-42 (2014).
- 19. Frost, S. et al. Retinal vascular biomarkers for early detection and monitoring of Alzheimer's disease. *Transl. Psychiatry.* **3**(2), e233 (2013).
- 20. Williams, M. A. et al. Retinal microvascular network attenuation in Alzheimer's disease. *Alzheimers Dement.* **1**(2), 229-35 (2015).
- 21. Williams, S. M. & Haines, J. L. Correcting away the hidden heritability. *Ann. Hum. Genet.* **75**(3), 348-50 (2011).
- 22. Trucco, E. et al. Validating retinal fundus image analysis algorithms: issues and a proposal. *Invest. Ophthalmol. Vis. Sci.* **54**(5), 3546-59 (2013).
- 23. Guo, X. et al. Blood pressure components and changes in relation to white matter lesions: a 32-year prospective population study. *Hypertension*. **54**, 57–62 (2009).
- 24. Heringa, S. M. et al. Associations between retinal microvascular changes and dementia, cognitive functioning, and brain imaging abnormalities: a systematic review. *J. Cereb. Blood Flow Metab.* **33**(7), 983-95 (2013).

- 25. Mimoun, L., Massin, P. & Steg, G. Retinal microvascularisation abnormalities and cardiovascular risk. *Arch. Cardiovasc. Dis.* **102**(5), 449-56 (2009).
- 26. Wong, T. Y. et al. Retinal microvascular abnormalities and 10-year cardiovascular mortality: a population-based case-control study. *Ophthalmology*. **110**(5), 933-40 (2003).
- 27. Debette, S. & Markus, H.S. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ*. **341**, c3666 (2010).
- 28. Deary, I. J. et al. The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond. *BMC Geriatr.* **7**(1), 28 (2007).
- 29. Deary, I. J., Gow, A. J., Pattie, A. & Starr, J. M. Cohort profile: the Lothian Birth Cohorts of 1921 and 1936. *Int. J. Epidemiol.* **41**(6), 1576-84 (2012).
- 30. Wardlaw, J. M. et al. Brain aging, cognition in youth and old age and vascular disease in the Lothian Birth Cohort 1936: rationale, design and methodology of the imaging protocol. *Int. J. Stroke.* **6**(6), 547-59 (2011).
- 31. Perez-Rovira, A. et al. VAMPIRE: vessel assessment and measurement platform for images of the REtina. In: Engineering in medicine and biology society, EMBC, 2011 annual international conference of the IEEE. Aug 30. 3391-94 (2011).
- 32. Trucco, E. et al. Novel VAMPIRE algorithms for quantitative analysis of the retinal vasculature. In: IEEE ISSNIP 2013: Biosignals and Biorobotics Conference (BRC), 1-4 (2013).
- 33. Trucco, E. et al. Morphometric measurements of the retinal vasculature in fundus images with VAMPIRE in *Biomedical Image Understanding* (ed. Lim, J-H., Ong, S-H., Xiong, W.) 91–112 (John Wiley & Sons Inc., 2015).
- 34. Wardlaw, J. M. et al. STandards for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* **12**(8), 822-38 (2013).
- 35. Fazekas, F., Chawluk, J. B., Alavi, A., Hurtig, H. I. & Zimmerman, R. A. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *AJR Am. J. Roentgenol.* **149**(2), 351-6 (1987).
- 36. Doubal, F. N., MacLullich, A. M., Ferguson, K. J., Dennis M. S. & Wardlaw, J. M. Enlarged perivascular spaces on MRI are a feature of cerebral small vessel disease. *Stroke.* **41**(3), 450-4 (2010).
- 37. Farrell, C. et al. Development and initial testing of normal reference MR images for the brain at ages 65–70 and 75–80 years. *Eur. Radiol.* **19**(1), 177-83 (2009).

- 38. Staals, J., Makin, S. D., Doubal, F. N., Dennis, M. S. & Wardlaw, J. M. Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden. *Neurology*. **83**(14), 1228-34 (2014).
- 39. Staals, J. et al. Total MRI load of cerebral small vessel disease and cognitive ability in older people. *Neurobiol. Aging.* **36**(10), 2806-11 (2015).
- 40. Valdés Hernández, M. D., Ferguson, K. J., Chappell, F. M. & Wardlaw, J. M. New multispectral MRI data fusion technique for white matter lesion segmentation: method and comparison with thresholding in FLAIR images. *Eur. Radiol.* **20**(7), 1684-91 (2010).
- 41. Benjamini, Y. & Yekutieli, D. The control of the false discovery rate in multiple testing under dependency. *Ann. Stat.* **29**(4), 1165-88 (2001).
- 42. Penke, L. & Deary, I. J. Some guidelines for structural equation modelling in cognitive neuroscience: the case of Charlton et al.'s study on white matter integrity and cognitive ageing. *Neurobiol. Aging.* **31**(9), 1656-60 (2010).
- 43. Valdés Hernández, M. D., Booth, T. & Murray, C. Brain white matter damage in aging and cognitive ability in youth and older age. *Neurobiol. Aging.* **34**(12), 2740-7 (2013).
- 44. Rosseel, Y. Lavaan: An R package for structural equation modeling and more. Version 0.5–12 (BETA). *J. Stat. Softw.* **48**(2), 1-36 (2012).